Perrigo Company plc Number of Reporting Units
Perrigo Company plc (PRGO) reported Number of Reporting Units of 2 reporting_unit for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:NumberOfReportingUnits · last filed 2026-02-26
- Perrigo Company plc number of reporting units for fiscal 2023 was 3.00 reportingUnit, a 0.00% change from fiscal 2022.
- Perrigo Company plc number of reporting units for fiscal 2022 was 3.00 reportingUnit, a 50.00% increase from fiscal 2021.
- Perrigo Company plc number of reporting units for fiscal 2021 was 2.00 reportingUnit, a 60.00% decline from fiscal 2020.
- Perrigo Company plc number of reporting units for fiscal 2020 was 5.00 reportingUnit.
reportingUnit
| Period end | Number of Reporting Units 12 month |
|---|---|
| 2023-12-31 | 3.00 reportingUnit 10-K · filed 2024-02-27 |
| 2022-12-31 | 3.00 reportingUnit 10-K · filed 2023-02-28 |
| 2021-12-31 | 2.00 reportingUnit 10-K · filed 2022-03-01 |
| 2020-12-31 | 5.00 reportingUnit 10-K · filed 2021-03-01 |
reporting_unit
| Period end | Number of Reporting Units 12 month |
|---|---|
| 2025-12-31 | 2.00 reporting_unit 10-K · filed 2026-02-26 |
| 2024-12-31 | 2.00 reporting_unit 10-K · filed 2025-02-28 |
| 2019-12-31 | 6.00 reporting_unit 10-K · filed 2020-02-27 |
| 2018-12-31 | 6.00 reporting_unit 10-K · filed 2019-02-27 |
| 2017-12-31 | 6.00 reporting_unit 10-K · filed 2018-03-01 |
segments
| Period end | Number of Reporting Units 6 month | Number of Reporting Units 9 month | Number of Reporting Units 12 month | Number of Reporting Units 12 month as first filed |
|---|---|---|---|---|
| 2017-09-30 | 7.00 segments 10-Q · filed 2017-11-09 | |||
| 2017-07-01 | 7.00 segments 10-Q · filed 2017-08-10 | |||
| 2016-12-31 | 7.00 segments 10-Q · filed 2017-05-30 | 9.00 segments 10-K · filed 2017-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |